E
Evosep
Biotech & Life Sciences · Odense, Denmark · Founded 2016
Develops new solutions to make clinical proteomics 100 times more robust and 10 times faster MoreLess
Evosep is a pioneering company in the field of clinical proteomics, focusing on developing advanced solutions that significantly enhance the robustness and speed of proteomic analyses. The company serves a diverse range of clients, including clinical laboratories, research institutions, and pharmaceutical companies, who require high-throughput and reliable proteomic data. Operating in the rapidly growing proteomics market, Evosep's business model revolves around the sale of specialized instruments and consumables, such as the Evosep One and Evotip, which are designed to streamline and improve the efficiency of proteomic workflows. The company generates revenue through direct sales of these products, as well as through service contracts and partnerships. By addressing the increasing demand for high-throughput and robust proteomic solutions, Evosep aims to bridge the gap between research and clinical applications, ultimately bringing proteomics closer to everyday clinical practice.
Keywords: clinical proteomics, high-throughput, robustness, Evosep One, Evotip, pharmaceutical, research institutions, proteomic workflows, service contracts, specialized instruments.
Talent graph
Evosep's talent
Source: Dealroom Talent Intelligence.
Investors
1 investor on Evosep's cap table
Sourced from Dealroom's funding history.

Global footprint
Where Evosep has talent and traffic
team presence
Market sentiment
What the market is saying about Evosep
An AI-synthesized read of the highest-engagement posts about Evosep on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Evosep on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.